- Home
- ACHL vs RFL Comparison
ACHL vs RFL Comparison
Compare ACHL & RFL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACHL
- RFL
- Stock Information
- Founded
- ACHL 2016
- RFL 2017
- Country
- ACHL United Kingdom
- RFL United States
- Employees
- ACHL N/A
- RFL N/A
- Industry
- ACHL Biotechnology: Biological Products (No Diagnostic Substances)
- RFL Real Estate
- Sector
- ACHL Health Care
- RFL Finance
- Exchange
- ACHL Nasdaq
- RFL Nasdaq
- Market Cap
- ACHL 40.4M
- RFL 48.4M
- IPO Year
- ACHL 2021
- RFL N/A
- Fundamental
- Price
- ACHL $1.07
- RFL $1.83
- Analyst Decision
- ACHL Hold
- RFL
- Analyst Count
- ACHL 3
- RFL 0
- Target Price
- ACHL $2.83
- RFL N/A
- AVG Volume (30 Days)
- ACHL 126.9K
- RFL 28.2K
- Earning Date
- ACHL 11-14-2024
- RFL 12-12-2024
- Dividend Yield
- ACHL N/A
- RFL N/A
- EPS Growth
- ACHL N/A
- RFL N/A
- EPS
- ACHL N/A
- RFL N/A
- Revenue
- ACHL N/A
- RFL $637,000.00
- Revenue This Year
- ACHL N/A
- RFL N/A
- Revenue Next Year
- ACHL N/A
- RFL N/A
- P/E Ratio
- ACHL N/A
- RFL N/A
- Revenue Growth
- ACHL N/A
- RFL 128.32
- 52 Week Low
- ACHL $0.63
- RFL $1.29
- 52 Week High
- ACHL $1.76
- RFL $2.50
- Technical
- Relative Strength Index (RSI)
- ACHL 65.39
- RFL 45.82
- Support Level
- ACHL $0.99
- RFL $1.74
- Resistance Level
- ACHL $1.07
- RFL $1.96
- Average True Range (ATR)
- ACHL 0.04
- RFL 0.10
- MACD
- ACHL -0.00
- RFL -0.01
- Stochastic Oscillator
- ACHL 80.31
- RFL 36.00
About ACHL Achilles Therapeutics plc
Achilles Therapeutics PLC is a biopharmaceutical company. It is developing AI-powered precision T-cell therapies targeting clonal neoantigens to treat solid tumors. The company has two ongoing trials, the CHIRON trial in patients with non-small-cell lung cancer and the THETIS trial in patients with recurrent or metastatic melanoma.
About RFL Rafael Holdings Inc. Class B
Rafael Holdings Inc, through its subsidiaries, is a clinical stage, oncology-focused pharmaceutical company committed to the development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells. The company is a significant investor in two clinical stage oncology companies, Cornerstone Pharmaceuticals, Inc., and LipoMedix Pharmaceuticals Ltd.